Some of these targets are involved in cell signaling, proliferation and survival, cellular stress response, apoptosis, etc. For example, mutations in some components of the NF-kB pathway especially its regulators like NFKB2, TRAF2, TRAF3, CYLD, NFKB1, TACI, NIK, REL, NFKB2, IKBA, CYLD, NEMO, etc., that are involved in both the canonical and non-canonical pathway plays a role in multiple myeloma development (105, 106). Here, CYLD is linked to plasma cell myeloma.